Laura Joszt
Vice President of Content at Pharmacy Times
Vice President of Content at American Journal of Managed Care
Vice President of Content at MJH Life Sciences
Vice President of Content at Chief Healthcare Executive
Editorial Director for @AJMC_Journal at @MJHLifeSciences
Articles
-
1 week ago |
ajmc.com | Laura Joszt
Operationalizing chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies for treating multiple myeloma and lymphoma requires managing an intricate balance of cost-effectiveness, patient care delivery, and emerging treatment strategies, according to panelists at an Institute for Value-Based Medicine (IVBM) event presented by The American Journal of Managed Care in Cleveland, Ohio.
-
1 week ago |
ajmc.com | Laura Joszt
Elevated body mass index (BMI) is a modifiable risk factor in acute lymphoblastic leukemia (ALL), with high BMI impacting patient outcomes and treatment efficacy.
-
1 week ago |
ajmc.com | Laura Joszt |Hayden E. Klein |David Awad
Captions were auto-generated. As value-based care models expand across the oncology landscape, pharmacists play a growing role in navigating the complex intersection of therapeutic innovation, fiscal responsibility, and patient access. In an interview with The American Journal of Managed Care®(AJMC®),David Awad, PharmD, BCOP, oncology pharmacy manager at Robert Wood Johnson University Hospital, described the balancing act pharmacy teams must perform in the current treatment landscape.
-
1 week ago |
ajmc.com | Laura Joszt |Coral Omene
There is an increasing role for artificial intelligence (AI) and other technology solutions to improve care delivery and improve access for patients in underserved and rural communities, said Coral Omene, MD, PhD, associate professor, Rutgers Cancer Institute and RWJBarnabas Health. This transcript has been lightly edited; captions were auto-generated. TranscriptIs there a role for AI in promoting and helping to facilitate value-based cancer care?
-
2 weeks ago |
ajmc.com | Laura Joszt
Patients with KMT2A rearrangements and NPM1 mutations have high risk and face unfavorable prognosis, but menin inhibitors are a new class of targeted agents with the potential to treat these subtypes.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 324
- Tweets
- 2K
- DMs Open
- No
RT @Michael_Chernew: It’s awards night in Nashville. Congrats to @IshaniG on winning the 2022 @AJMC_Journal Seema Sonnad Emerging Leader in…
Alzheimer Disease Drug Lecanemab Successfully Reduces Cognitive, Functional Decline https://t.co/zKtFQBEvku via @AJMC_Journal https://t.co/U4DZRlD3kj
FDA Advisory Committee Gives Positive Vote for Microbiota-based C. Diff Therapy https://t.co/sdopevbiYn via @denise_myshko https://t.co/dHHUble7Q7